Cardiol Therapeutics (TSE:CRDL) Trading Up 3.4% - What's Next?

Key Points

• Cardiol Therapeutics Inc. shares increased by 3.4% on Wednesday, trading between C$1.45 and C$1.57, with a significant trading volume boost of 60% over the daily average.
• The company has a market capitalization of C$125.59 million, with a P/E ratio of -3.13 and a relatively low beta of 0.95.
• Cardiol Therapeutics is focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease, with its lead candidate, CardiolRxTM, in clinical development.

Cardiol Therapeutics Inc. (TSE:CRDL - )'s share price rose 3.4% during trading on Wednesday . The stock traded as high as C$1.57 and last traded at C$1.50. Approximately 159,808 shares traded hands during mid-day trading, an increase of 60% from the average daily volume of 99,597 shares. The stock had previously closed at C$1.45.

Cardiol Therapeutics Stock Performance

The company has a market cap of C$125.59 million, a P/E ratio of -3.13 and a beta of 0.95. The company has a quick ratio of 6.84, a current ratio of 2.49 and a debt-to-equity ratio of 1.59. The stock has a 50 day moving average price of C$1.71 and a two-hundred day moving average price of C$1.64.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc NASDAQ: CRDL TSX: CRDL is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead drug candidate, CardiolRxTM (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.